The helicobacter pylori testing market is expected to progress at an exponential rate by 2027 owing to growing incidences of gastric ulcers worldwide.

Helicobacter pylori is a type of bacteria that is known to cause the development of peptic ulcers, which are lesions on the lining of the esophagus, stomach, or small intestine. H. pylori testing reveals a bacterial infection of the digestive tract, which can aid in the identifying the cause of ulcers and symptoms. Notably, prevalent adoption of non-invasive H. pylori testing has augmented industry uptake in recent years.

Moreover, industry players have been employing various lucrative strategies to gain a competitive edge in the market, thereby strengthening the overall business landscape. For instance, in October 2021, Cardinal Health Specialty Solutions, a leading healthcare services provider, entered into an agreement with Gastrologix, a major GI-focused group purchasing organization (GPO). According to the deal, Cardinal Health's Metro Medical business was deemed the key supplier for providing pharmaceutical products to Gastrologix GPO, thereby offering widespread access of essential medicines to GI patients across the world.

The helicobacter pylori testing market has been segregated based on end-use, test type, method, and region. From the test type perspective, the market has further been divided into non-invasive and invasive.

The invasive sub-segment attained a valuation of over USD 129 million in 2020 and is slated to progress at a CAGR of approximately 10.7% over the assessment period. Invasive testing type offers enhanced outcomes due to efficient and accurate testing as well as improved efficiency, which is likely to boost product demand in the forthcoming years.

With respect to method, the helicobacter pylori testing market has been categorized into laboratory based test and point-of-care (POC) test. In 2020, the point-of-care (POC) test sub-segment was valued at more than USD 107 million and is projected to register around 12.3% market growth through the review period. Surging demand for point-of-care (POC) testing in the diagnosis of the helicobacter pylori infection is likely to boost segmental growth over the stipulated timeline.

In terms of end-use, the helicobacter pylori testing market has been bifurcated into diagnostic laboratories, hospitals, clinics, and others. The hospitals sub-segment surpassed a valuation of USD 91 million in 2020 and is anticipated to witness notable expansion over the study timeframe. This growth is attributed to the increasing availability of board-certified skilled doctors, high success rate, and faster & more efficient work, among others.

On the regional front, the Latin America helicobacter pylori testing market was worth nearly USD 21 million in 2020 and is estimated to grow at above 11.1% CAGR through the analysis period. Rising prevalence of gastric cancer, along with increasing awareness regarding the helicobacter pylori infection, is set to bolster regional market expansion in the coming time period.